Navigation Links
Prostate Cancer Risk Linked To Early Estrogen Exposure

Exposure to estrogens in the early stages of the development of the prostate gland in the male fetus is a factor cited by the scientists for the development of the prostate cancer at the later part of life. //

The study, done in an animal model, also demonstrates how the predisposition may arise, and a way to identify those at risk.

Man-made compounds that can mimic the hormone action of estrogens (xenoestrogens) are widespread in the environment. One of these agents is bisphenol A (BPA), used in the manufacture of plastics and epoxy resins. The United States alone produces over 1.6 million pounds of BPA annually. BPA, which can also leach from plastics when heated, turns up in human blood and in placental and fetal tissues in even higher concentrations.

In this study, a research team led by Dr. Gail Prins of the University of Illinois at Chicago and Dr. Shuk-Mei Ho of the University of Cincinnati exposed rats to low doses of estradiol, a natural estrogen, or to BPA during the developmental period corresponding to the second and third trimester of human pregnancy. They found that this early exposure predisposed male rats to precancerous lesions of the prostate in old age.

Most remarkably, early BPA exposure sensitized the prostate to precancerous lesions brought on by exposure of the adult animal to elevated estradiol, said Prins, professor of urology at UIC and senior author of the study. "This is highly relevant to people, because relative estradiol levels increase in aging men as a result of their increased body fat and declining testosterone levels.

The doses of estradiol and BPA used in the study were similar to levels found in human serum; in the circulation of some pregnant women; and in the fetus. Transfer of BPA from mother to fetus has been reported, and levels in male fetuses have been shown to be higher than those of female fetuses.

The researchers were able to demonstrate that early estrogen or BPA exposure permanently changed the methylation, or tagging, of specific stretches of DNA in the neonate's prostate cells, a phenomenon referred to as epigenetic reprogramming. In epigenetic reprogramming, gene expression is altered without changing DNA sequences or content. Several of the epigenetically altered sites turned out to be in important genes that regulate cellular functions.

The researchers conclude that exposure to environmental estrogens, such as BPA, or natural estrogens affect the pattern of gene expression in the prostate during development, and in so doing promote prostate disease with aging.

One of the altered genes, phosphodiesterase 4 (PDE4D4), was examined in greater detail. The researchers found that the methylation of PDE4D4 can permanently change its pattern of expression in the prostate. This gene should normally shut down in adult life, but after early exposure to estradiol or BPA, the exposed animals' prostates continued to express it at high levels. Similar high levels due to methylation of the gene were found in prostate cancer cells but not in normal cell lines.

Because the methylation marks of epigenetic reprogramming were found before any disease was observed, the methylation may be useful as a way to identify men at higher prostate disease risk, Prins said, which may have resulted from early exposure to endocrine disruptors.

These findings are true for an animal model, and application to human prostate disease will await future studies, the authors concluded. Ho is first author of the study and professor and chairman of environmental health at the University of Cincinnati.

(Source: Newswise)
'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
3. New Prostate Cancer Vaccine Shows Promise
4. Hormone Therapy applicable for Prostate Cancer
5. Prostate cancer and Vitamins
6. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
7. Early Detection Of Prostate Cancer
8. Awareness increase Prostate cancer detection
9. Better Prostate Cancer Test
10. Stopping Prostate Cancer from Spreading
11. Drug might prevent Prostate Cancer Spread
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... ... ... Tijuana Bariatrics is pleased to announce that the fourth floor of CER Hospital, ... This means that the practice’s network of doctors can now treat and accommodate more ... ability to treat patients from San Diego and other U.S. cities that are looking ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... TX has announced the latest beneficiary of their ongoing community enrichment program. The ... childhood leukemia. Young Mason McGaughey faces many more months of treatments, leaving his ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... DrugDev ... in changing the way the pharmaceutical industry conducts clinical trials. This month Ibs was ... influential people in pharma, and he was honored as a Tech Disruptor by the ...
(Date:5/6/2016)... AZ (PRWEB) , ... May 06, 2016 , ... ... Greater Odds, are scheduled to provide a unique keynote address at the ... follows the inspirational stories of five community college students. Their stories—of complicated family ...
(Date:5/6/2016)... ... , ... A wide variety of national pet product manufacturers, companies and brands will gather for ... May 18 from noon to 8 p.m. at New York City’s Roger Smith Hotel. The ... home, garden, outdoor and safety pet products in today’s marketplace. , Petrend Event ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... , May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... of Directors declared a fiscal year 2016 third quarter ... percent increase over the amount paid a year ago. ... record as of the close of business on June 10, ...    Hill-Rom is a leading global medical technology ...
(Date:5/5/2016)... Ltd. today reported initial promising results in animal trials of its Zika vaccine candidates. ... ... ... ... Pubmed. The analysis identified the highest gene Replikin Counts in Zika history back to ...
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
Breaking Medicine Technology: